Brief: Fluicell Resolves On Rights Issue Of SEK 30.5 Mln

Fluicell AB

30/08/2022 08:30

Aug 30 (Reuters) - Fluicell AB  FLUIC.ST :
    * SAID ON MONDAY BOARD RESOLVED ON RIGHTS ISSUES OF UNITS OF
INITIALLY UP TO SEK 30.5 MLN
    * CAPITAL INCREASE TO FINANCE ONGOING OPERATIONS UP TO AND
INCLUDING SPRING 2024
    * DURING THIS PERIOD THE COMPANY AIMS TO MOVE ON WITH AT
LEAST ONE
REGENERATIVE MEDICAL PRODUCT TO PRECLINICAL DEVELOPMENT PHASE
AND TO LAUNCH HUMAN TISSUE-BASED DISEASE MODELS FOR DRUG
DEVELOPMENT 
    * UP TO ABOUT 80% OF RIGHTS ISSUE IS COVERED BY SUBSCRIPTION
OBLIGATIONS AND GUARANTEE COMMITMENTS FROM BOARD, SENIOR
EXECUTIVES AND EXTERNAL INSTITUTIONAL, OTHER PROFESSIONAL
INVESTORS
    * ONE (1) UNIT CONSISTS OF FIVE (5) NEWLY ISSUED SHARES AND
TWO
(2) WARRANTS OF SERIES TO 4
    * SUBSCRIPTION PRICE FOR RIGHTS ISSUE IS SET AT SEK 12.50
PER
UNIT, CORRESPONDING TO SEK 2.50 PER SHARE
    * FULL EXERCISE OF WARRANTS OF SERIES TO 4 AT THE HIGHEST
SUBSCRIPTION PRICE, WITHIN THE FRAMEWORK OF ISSUED UNITS, CAN
GENERATE ADDITIONAL PROCEEDS OF UP TO ABOUT SEK 20.5 MLN
    * RIGHTS ISSUE WILL HAVE A DILUTION EFFECT CORRESPONDING TO
ABOUT
45.45%

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkr3G9yVM
 Further company coverage:  FLUIC.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))